MAZE
Maze Therapeutics Inc.

55
Mkt Cap
$1.57B
Volume
912,658.00
52W High
$34.29
52W Low
$6.71
PE Ratio
-14.43
MAZE Fundamentals
Price
$32.53
Prev Close
$31.84
Open
$31.99
50D MA
$27.53
Beta
1.08
Avg. Volume
329,417.96
EPS (Annual)
$0.0778
P/B
4.12
Rev/Employee
$1.34M
Loading...
Loading...
News
all
press releases
Maze Therapeutics (NASDAQ:MAZE) Sees Strong Trading Volume - Here's Why
Maze Therapeutics (NASDAQ:MAZE) Sees Strong Trading Volume - What's Next...
MarketBeat·19h ago
News Placeholder
More News
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Given New $36.00 Price Target at Wedbush
Wedbush upped their price objective on Maze Therapeutics from $35.00 to $36.00 and gave the company an "outperform" rating in a research note on Friday...
MarketBeat·8d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Releases Earnings Results, Beats Expectations By $0.08 EPS
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.66) earnings per share (EPS) for the quarter, beating the consensus...
MarketBeat·8d ago
News Placeholder
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 9.6% - Here's What Happened
Maze Therapeutics (NASDAQ:MAZE) Trading Down 9.6% - Here's What Happened...
MarketBeat·10d ago
News Placeholder
Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION) For access to live and exclusive video from CNBC subscribe to CNBC PRO: https://cnb.cx/42d859g Subscribe to CNBC TV: https://cnb.cx/SubscribeCNBCtelevision...
CNBC Television-YouTube·19d ago
News Placeholder
Maze Therapeutics Stock Just Shot Up 56% Pre-Market Today – Here’s What Happened
The company announced a private placement for over four million shares of common stock at $16.25 apiece, representing a premium of over 1% from the stock’s closing price on Wednesday.
Stocktwits·2mo ago
News Placeholder
Maze Therapeutics receives positive ratings following recent IPO
Investing.com -- Maze Therapeutics Inc (NASDAQ:MAZE) received bullish coverage from multiple analysts, with Guggenheim, JPMorgan, and TD Cowen initiating Buy or Overweight ratings on the company given its potential in genetically targeted therapies.
investing.com·9mo ago

Latest MAZE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.